Review finds small studies link liraglutide and semaglutide to psoriasis improvement
The review gathers early, small studies suggesting GLP-1 drugs may ease psoriasis, but reports no data yet on whether they change the course of psoriatic arthritis.
A review published April 27 in the journal Frontiers in Immunology maps what is known about GLP-1 receptor agonists in psoriasis and psoriatic arthritis, and concludes that small studies point to skin benefits while joint evidence remains preliminary [1].
The paper is a narrative review by rheumatology researchers at the University of Modena and Reggio Emilia and the University of Ferrara in Italy. It covers preclinical, clinical and mechanistic research on these drugs in psoriasis (PsO) and psoriatic arthritis (PsA) [1]. It is not new trial data.
What the human studies found
The review says several studies show that GLP-1 receptor agonists, particularly liraglutide and semaglutide, improve psoriasis severity, metabolic measures and inflammatory markers, and that the skin benefits appear to go beyond weight loss, suggesting a direct effect on the immune system [1].
The individual studies it cites are small. A 2011 case series reported two patients with psoriasis and type 2 diabetes treated with liraglutide; it described a drop in PASI, a standard psoriasis severity score, along with laboratory work in which GLP-1 inhibited cytokine secretion in a dose-dependent way [1]. A 2012 prospective cohort of seven patients with psoriasis, obesity and type 2 diabetes on liraglutide reported lower PASI and lower BMI [1]. A 2013 single case report described a 54-year-old man with psoriasis and obesity treated with liraglutide plus acitretin who also had a lower PASI and BMI [1].
For psoriatic arthritis, the review says two open-label trials in patients with PsA and obesity indicated improvements in disease activity (MDA) alongside metabolic benefits [1]. The review names them as NCT06588296 (TOGETHER-PsA) and NCT06864026 (TOGETHER AMPLIFY-PsA), and says they assessed ixekizumab with and without tirzepatide [1].
The authors describe the PsA evidence as limited and say most studies are constrained by small sample sizes and short follow-up. They also write that no studies have specifically investigated GLP-1 receptor agonists in early PsA [1].
Why it matters for patients
Psoriasis affects 2 to 3 percent of the global population, and up to 30 percent of people with psoriasis eventually develop psoriatic arthritis [1]. The two conditions share metabolic risk factors: patients with psoriatic arthritis have a higher prevalence of metabolic syndrome than people with psoriasis alone or rheumatoid arthritis, and obesity is tied to both higher PsA incidence and weaker responses to biologic drugs [1].
That overlap is why GLP-1 drugs are being studied here. Many patients with psoriatic disease already take them for type 2 diabetes or obesity, and the review's question is whether the drugs also calm inflammation in skin and joints [1]. The review does not show that. It reports a hypothesis supported by small studies, and its authors state that the early-PsA idea requires validation in dedicated clinical studies [1]. It offers no dosing guidance and no recommendation that these drugs be used to treat psoriasis or psoriatic arthritis.
What happens next
The review lists ongoing trials that are expected to clarify the role of GLP-1 receptor agonists in psoriatic disease and other immune-mediated inflammatory diseases [1]. It does not report results for TOGETHER-PsA or TOGETHER AMPLIFY-PsA, and gives no completion dates for either study [1]. No timeline has been disclosed for trials that would test these drugs in early psoriatic arthritis [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.